HCP5 and neoplasm: To verify whether the expression of serum HCP5 was related to tumor dynamic monitoring, we compared serum HCP5 in unpaired samples, including 98 patients with primary gastric cancer, 46 patients with surgical treatment, and 57 patients with tumor recurrence.